// STATE LEGISLATION TRACKER

Pennsylvania SB 866: An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Passed chamber

State: Pennsylvania
Bill: SB 866
Session: 2025-2026
Filed: 2025-07-24
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

Pennsylvania SB866 would classify medetomidine as a Schedule III controlled substance while keeping listed veterinary and federally authorized uses outside that control. It is aimed at xylazine/medetomidine drug-control policy, not peptide compounding, off-label peptide prescribing, telehealth, or NP/naturopath scope.

Key Points

No direct peptide access change is apparent from the bill text
Compounded peptides are not named or targeted
Telehealth prescribing rules are not addressed
NP and naturopathic scope is not expanded or restricted
Medetomidine controls may matter only if a clinic handles that drug

What to Watch For

Note Watch whether House amendments broaden the bill beyond medetomidine and xylazine.

Concern Clinics using medetomidine may face controlled-substance handling and storage duties.

Note The bill does not appear to change FDA 503A or 503B peptide compounding rules.

Where the Bill Stands

The bill passed the Pennsylvania Senate on June 9, 2026 and was referred to the House Judiciary Committee on June 10, 2026.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws